Compare Citius Pharmaceuticals Inc (CTXR) vs Vanguard Tax Managed Fund FTSE Developed Markets ETF (VEA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Vanguard Tax Managed Fund FTSE Developed Markets ETF — how do they compare? Citius Pharmaceuticals Inc trades at $0.73 (market cap $18.73M), while Vanguard Tax Managed Fund FTSE Developed Markets ETF trades at $72.71. The key difference: Vanguard Tax Managed Fund FTSE Developed Markets ETF is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | VEA | |
|---|---|---|
Market Cap | $18.73M | — |
Sector | Health | — |
52-Week High | $1.82 | $72.89 |
52-Week Low | $0.48 | $58.19 |
Enterprise Value | $14.95M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR is trading at $0.68, up 6.28% today, with a bullish technical signal from moving averages. The company shows strong commercial momentum with LYMPHIR cancer treatment revenue reaching $5.6 million in H1 2026, though it remains unprofitable with a -823% net margin. Analyst consensus is strongly bullish with 83% buy ratings.
The outlook depends on LYMPHIR's commercial success offsetting deep losses. Near-term catalysts include expanded market access and combination therapy data, but high cash burn and execution risks require monitoring. The stock offers speculative growth potential in oncology but carries significant financial risk.
VEA trades at $72.89, up 1.07% today, with a bullish technical outlook supported by moving averages. The ETF focuses on developed markets outside the U.S., offering low-cost diversification. Recent news highlights mixed institutional activity, with some firms increasing stakes while others reduce holdings, reflecting varied sentiment toward international equity exposure.
The outlook for VEA is supported by its low expense ratio and diversification benefits, but risks include currency fluctuations and geopolitical tensions in developed markets. Analyst comparisons favor VEA for cost efficiency, though performance relative to U.S. indices remains a key consideration for investors seeking global allocation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Vanguard Tax Managed Fund FTSE Developed Markets ETF
The fund employs an indexing investment approach designed to track the performance of the FTSE Developed All Cap ex US Index, a market-capitalization-weighted index that is made up of approximately 4022 common stocks of large-, mid-, and small-cap companies located in Canada and the major markets of Europe and the Pacific region. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VEA →
